Literature DB >> 2236748

Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors.

D Hattis1, P White, L Marmorstein, P Koch.   

Abstract

In recent years physiologically based pharmacokinetic models have come to play an increasingly important role in risk assessment for carcinogens. The hope is that they can help open the black box between external exposure and carcinogenic effects to experimental observations, and improve both high-dose to low-dose and interspecies projections of risk. However, to date, there have been only relatively preliminary efforts to assess the uncertainties in current modeling results. In this paper we compare the physiologically based pharmacokinetic models (and model predictions of risk-related overall metabolism) that have been produced by seven different sets of authors for perchloroethylene (tetrachloroethylene). The most striking conclusion from the data is that most of the differences in risk-related model predictions are attributable to the choice of the data sets used for calibrating the metabolic parameters. Second, it is clear that the bottom-line differences among the model predictions are appreciable. Overall, the ratios of low-dose human to bioassay rodent metabolism spanned a 30-fold range for the six available human/rat comparisons, and the seven predicted ratios of low-dose human to bioassay mouse metabolism spanned a 13-fold range. (The greater range for the rat/human comparison is attributable to a structural assumption by one author group of competing linear and saturable pathways, and their conclusion that the dangerous saturable pathway constitutes a minor fraction of metabolism in rats.) It is clear that there are a number of opportunities for modelers to make different choices of model structure, interpretive assumptions, and calibrating data in the process of constructing pharmacokinetic models for use in estimating "delivered" or "biologically effective" dose for carcinogenesis risk assessments. We believe that in presenting the results of such modeling studies, it is important for researchers to explore the results of alternative, reasonably likely approaches for interpreting the available data--and either show that any conclusions they make are relatively insensitive to particular interpretive choices, or to acknowledge the differences in conclusions that would result from plausible alternative views of the world.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2236748     DOI: 10.1111/j.1539-6924.1990.tb00528.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  5 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Fuzzy simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam.

Authors:  Ivelina I Gueorguieva; Ivan A Nestorov; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

3.  Toxicity testing in the 21st century: a vision and a strategy.

Authors:  Daniel Krewski; Daniel Acosta; Melvin Andersen; Henry Anderson; John C Bailar; Kim Boekelheide; Robert Brent; Gail Charnley; Vivian G Cheung; Sidney Green; Karl T Kelsey; Nancy I Kerkvliet; Abby A Li; Lawrence McCray; Otto Meyer; Reid D Patterson; William Pennie; Robert A Scala; Gina M Solomon; Martin Stephens; James Yager; Lauren Zeise
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2010-02       Impact factor: 6.393

Review 4.  Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment.

Authors:  D Krewski; J R Withey; L F Ku; M E Andersen
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

Review 5.  Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment.

Authors:  H J Clewell; P R Gentry; T R Covington; J M Gearhart
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.